Gregory Scott Day

Gregory Scott Day

Auto-generated profile, based on publicly available information

Gregory Scott Day

Department of Neurology, Mayo Clinic, Jacksonville, FL; and

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
RPRonald C. Petersen
Ronald C. Petersen
OLOscar Lopez
Oscar Lopez
MAMelissa J. Armstrong
Melissa J. Armstrong
TGThomas S.D. Getchius
Thomas S.D. Getchius
MGMary Ganguli
Mary Ganguli
ARAlexander Rae-Grant
Alexander Rae-Grant
Objective To update the 2001 American Academy of Neurology (AAN) guideline on mild cognitive impairment (MCI). Methods The guideline panel systematically reviewed MCI prevalence, prognosis, and treatment articles according to AAN evidence classification criteria, and based recommendations on evidence and modified Delphi consensus. Results MCI prevalence was 6.7% for ages 60–64, 8.4% for 65–69, 10.1% for 70–74, 14.8% for 75–79, and 25.2% for 80–84. Cumulative dementia incidence was 14.9% in individuals with MCI older than age 65 years followed for 2 years. No high-quality evidence exists to support pharmacologic treatments for MCI. In patients with MCI, exercise training (6 months) is likely to improve cognitive measures and cognitive training may improve cognitive measures. Major recommendations Clinicians should assess for MCI with validated tools in appropriate scenarios (Level B). Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms (Level B). Clinicians should monitor cognitive status of patients with MCI over time (Level B). Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated (Level B). Clinicians may choose not to offer cholinesterase inhibitors (Level B); if offering, they must first discuss lack of evidence (Level A). Clinicians should recommend regular exercise (Level B). Clinicians may recommend cognitive training (Level C). Clinicians should discuss diagnosis, prognosis, long-term planning, and the lack of effective medicine options (Level B), and may discuss biomarker research with patients with MCI and families (Level C).

23 April 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
ARAlexander Rae-Grant
Alexander Rae-Grant
GDGregory S. Day
Gregory S. Day
RMRuth Ann Marrie
Ruth Ann Marrie
ARAlejandro Rabinstein
Alejandro Rabinstein
BCBruce A.C. Cree
Bruce A.C. Cree
TPTamara Pringsheim
Tamara Pringsheim
Objective: To develop recommendations for disease-modifying therapy (DMT) for multiple sclerosis (MS).Methods: A multidisciplinary panel developed DMT recommendations, integrating findings from a systematic review; followed an Institute of Medicine–compliant process to ensure transparency and patient engagement; and developed modified Delphi consensus–based recommendations concerning starting, switching, and stopping DMTs pertinent to people with relapsing-remitting MS, secondary progressive MS, primary progressive MS, and clinically isolated syndromes of demyelination. Recommendations were supported by structured rationales, integrating evidence from one or more sources: systematic review, related evidence (evidence not from the systematic review), principles of care, and inference from evidence.Results: Thirty recommendations were developed: 17 on starting DMTs, including recommendations on who should start them; 10 on switching DMTs if breakthrough disease develops; and 3 on stopping DMTs. Recommendations encompassed patient engagement strategies and individualization of treatment, including adherence monitoring and disease comorbidity assessment. The panel also discussed DMT risks, including counseling about progressive multifocal leukoencephalopathy risk in people with MS using natalizumab, fingolimod, rituximab, ocrelizumab, and dimethyl fumarate; and made suggestions for future research to evaluate relative merits of early treatment with higher potency DMTs vs standard stepped-care protocols, DMT comparative effectiveness, optimal switching strategies, long-term effects of DMT use, definitions of highly active MS, and effects of treatment on patient-specified priority outcomes. This guideline reflects the complexity of decision-making for starting, switching, or stopping MS DMTs. The field of MS treatment is rapidly changing; the Academy of Neurology development process includes planning for future updates.

21 August 2018 in Neurology
Verified
Journal Article
Closed access
PDF file
RPRonald C. Petersen
Ronald C. Petersen
OLOscar Lopez
Oscar Lopez
MAMelissa J. Armstrong
Melissa J. Armstrong
TGThomas S.D. Getchius
Thomas S.D. Getchius
MGMary Ganguli
Mary Ganguli
ARAlexander Rae-Grant
Alexander Rae-Grant
We thank Drs. Gang Wang and Hai-lun Cui, Valenzuela et al., and Dr. Braillon for the comments on the recently published mild cognitive impairment (MCI) guideline.1

16 November 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
TPTamara Pringsheim
Tamara Pringsheim
GDGregory S. Day
Gregory S. Day
DSDon B. Smith
Don B. Smith
ARAlex Rae-Grant
Alex Rae-Grant
NLNicole Licking
Nicole Licking
JGJulie Gurwell
Julie Gurwell
Background and Objectives To review the current evidence on the options available for initiating dopaminergic treatment of motor symptoms in early-stage Parkinson disease and provide recommendations to clinicians. Methods A multidisciplinary panel developed practice recommendations, integrating findings from a systematic review and following an Institute of Medicine–compliant process to ensure transparency and patient engagement. Recommendations were supported by structured rationales, integrating evidence from the systematic review, related evidence, principles of care, and inferences from evidence. Results Initial treatment with levodopa provides superior motor benefit compared to treatment with dopamine agonists, whereas levodopa is more likely than dopamine agonists to cause dyskinesia. The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration is superior. Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release levodopa for motor symptoms in early disease. There is a higher risk of impulse control disorders associated with the use of dopamine agonists than levodopa. Recommendations on initial therapy for motor symptoms are provided to assist the clinician and patient in choosing between treatment options and to guide counseling, prescribing, and monitoring of efficacy and safety.

7 August 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
EJErik C. B. Johnson
Erik C. B. Johnson
SBShijia Bian
Shijia Bian
RHRafi U. Haque
Rafi U. Haque
ECE. Kathleen Carter
E. Kathleen Carter
CWCaroline M. Watson
Caroline M. Watson
ALAllan I. Levey
Allan I. Levey
Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)—are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aβ plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aβ plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aβ and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aβ and tau.

1 October 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
HPHarry E. Peery
Harry E. Peery
GDGregory S. Day
Gregory S. Day
SDShannon Dunn
Shannon Dunn
MFMarvin J. Fritzler
Marvin J. Fritzler
HPHarald Prüss
Harald Prüss
WFWarren G. Foster
Warren G. Foster